BNN Bloomberg: An Interview with Dr. Gilly Regev of SaNOtize


U.K. clinical trials for Vancouver’s SaNOtize have confirmed that its nasal spray reduced SARS-CoV-2 log viral load by more than 95 per cent in infected participants within 24 hours of treatment, and by more than 99 per cent in 72 hours. While the product is set to sell over the counter in Israel and New Zealand pharmacies, Dr. Gilly Regev says Health Canada sees their product as a drug and not a medical device, hindering the ability for SaNOtize to be available to the Canadian market sooner rather than later.

Leave a comment

All blog comments are checked prior to publishing
You have successfully subscribed!
This email has been registered